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Chlamydia trachomatis is a pathogen of the genital tract and ocular epithelium. Infection is established by the
binding of the metabolically inert elementary body (EB) to epithelial cells. These are taken up by endocytosis
into a membrane-bound vesicle termed an inclusion. The inclusion avoids fusion with host lysosomes, and the
EBs differentiate into the metabolically active reticulate body (RB), which replicates by binary fission within
the protected environment of the inclusion. During the extracellular EB stage of the C. trachomatis life cycle,
antibody present in genital tract or ocular secretions can inhibit infection both in vivo and in tissue culture.
The RB, residing within the intracellular inclusion, is not accessible to antibody, and resolution of infection at
this stage requires a cell-mediated immune response mediated by gamma interferon-secreting Th1 cells. Thus,
an ideal vaccine to protect against C. trachomatis genital tract infection should induce both antibody (immu-
noglobulin A [IgA] and IgG) responses in mucosal secretions to prevent infection by chlamydial EB and a
strong Th1 response to limit ascending infection to the uterus and fallopian tubes. In the present study we show
that transcutaneous immunization with major outer membrane protein (MOMP) in combination with both
cholera toxin and CpG oligodeoxynucleotides elicits MOMP-specific IgG and IgA in vaginal and uterine lavage
fluid, MOMP-specific IgG in serum, and gamma interferon-secreting T cells in reproductive tract-draining
caudal and lumbar lymph nodes. This immunization protocol resulted in enhanced clearance of C. muridarum
(C. trachomatis, mouse pneumonitis strain) following intravaginal challenge of BALB/c mice.
Chlamydia trachomatis is the leading cause of bacterial sex-
ually transmitted disease worldwide. It is an obligate intracel-
lular bacterial pathogen that infects the epithelium of the gen-
ital and ocular mucosa. In 1999, the World Health
Organization estimated that 92 million cases of C. trachomatis
genital infections occurred worldwide, with an estimated 4 to 5
million new cases occurring annually in the United States (69).
The majority of infections occur in teenagers and people under
30 years of age. The majority of genital tract infections
(85%) in women are asymptomatic (reviewed in reference
6), masking the serious pathological consequences that can
result from infection. In males, 45% of infections are asymp-
tomatic. For women, the vaginal-cervical infection can spread
to the upper reproductive tract, leading to serious complica-
tions which include chronic and recurrent pelvic inflammatory
disease, fallopian tube scarring, ectopic pregnancy, chronic
pelvic pain, and infertility (66). A recent report (13) by the
Institute of Medicine estimates the annual direct and indirect
costs of non-human immunodeficiency virus sexually transmit-
ted diseases in the United States to be $10 billion, with ap-
proximately $4 billion of this due to C. trachomatis infections.
Although effective antimicrobial treatment is available, this has
been largely unsuccessful in halting the spread of infection,
most likely due to the high rate of asymptomatic infections,
which may persist for months to years (57). Multiple-antibiotic-
resistant strains of Chlamydia have also been reported recently
(56). Furthermore, it has been suggested that antibiotic treat-
ment can result in persistent infections with aberrant forms of
C. trachomatis that may be reactivated at a later date (19).
Recent studies also suggest that Chlamydia infection of the
lower genital tract may be an important risk factor facilitating
sexual transmission of human immunodeficiency virus infec-
tion (23). Thus, improved means of prevention and control of
C. trachomatis genital tract infections are urgently required,
particularly the development of a vaccine to prevent infection
by inducing protection at mucosal surfaces. Vaccine-induced
immunity will need to be more effective than that produced by
natural infection. Infection induces both antibody- and cell-
mediated immunity that declines over time and is insufficient
to prevent reinfection with other serovars.
Despite many studies of animal models and infected hu-
mans, the type(s) of immunity needed to protect against gen-
ital tract chlamydial infection has not been well defined (3).
CD4 Th1 responses, characterized by high levels of gamma
interferon (IFN-) production (10, 48), are implicated as the
major mechanism of clearance of Chlamydia in mouse and
primate models, with antibody being of lesser importance.
Only mice deficient in T-cell receptor  and major histocom-
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patibility complex class II (MHC-II) genes are incapable of
resolving genital infections (44, 48). Complete resolution of
infection in the guinea pig model appears to require both
antibody and cell-mediated immunity (CMI) (1, 51). Antibody,
both serum immunoglobulin G (IgG) and local IgA, has been
shown to play a role in clearance of Chlamydia from the genital
tract in the mouse, guinea pig, primate, and marmoset models
(50). Antibody is particularly important in recall immunity, as
mice deficient in antibody are less resistant to reinfection than
mice with local antichlamydial antibody (60). This is supported
by studies of infected humans, which showed an inverse cor-
relation between IgA levels in cervical secretions and the
amount of Chlamydia recovered from the cervix (4). Antibody
may (i) neutralize Chlamydia and reduce ascending infection
by blocking chlamydial attachment to epithelial cells; (ii) en-
hance killing of opsonized Chlamydia by phagocytic cells,
thereby limiting dissemination to distant sites; or (iii) contrib-
ute to the resolution of intracellular infection by antibody-
dependent cellular cytotoxicity (42). The role of CD8 cells is
unclear. Adoptive transfer studies of fractionated CD4 and
CD8 cells and the use of CD8-cell-deficient mice all suggest
that CD8 cells play a minor role, if any, in protection against
chlamydial genital infection (44, 45), and that any effect is
likely to be due to production of IFN- (36). Furthermore,
infection of mice genetically deficient in perforin, Fas, or Fas
ligand or in double-knockout mice deficient in both perforin
and Fas ligand showed that these mice cleared primary chla-
mydial infections with kinetics nearly identical to those ob-
served in wild-type control mice and were resistant to reinfec-
tion (49). Chlamydia can also inhibit both constitutive and
IFN--induced MHC-I expression by infected cells, due to
degradation of the transcription factor RFX5 by a chlamydial
protease (74), and inhibit apoptosis in target cells by prevent-
ing caspase activation (14). This would also be expected to
limit the effectiveness of cytotoxic T lymphocyte (CTL) killing.
There are, however, reports of the identification of human
CD8 CTLs specific for chlamydial peptides from individuals
with documented C. trachomatis infection. Using HLA class I
tetramers Kim et al. (31) identified major outer membrane
protein (MOMP)-specific CD8 CTLs in the peripheral blood
of infected individuals. Peripheral blood mononuclear cells
from individuals infected with C. trachomatis (30) and C. pneu-
moniae (68) include CD8 cells that are able to lyse histocom-
patible Chlamydia peptide-pulsed epithelial cells and Chlamy-
dia-infected cell lines following multiple rounds of in vitro
stimulation with HLA-binding peptides derived from the chla-
mydial MOMP. These data show that CD8 CTLs are induced
by natural infection and that, after in vitro stimulation with
defined chlamydial peptides, expanded cells can kill Chlamy-
dia-infected targets. Furthermore, large numbers of cloned
CD8 CTLs can partially protect naive mice against challenge,
due to production of IFN- (24, 30, 58, 59). However, a direct
protective role for CD8 CTLs in vivo has not yet been dem-
onstrated, and it is widely accepted that CD8 T cells are nei-
ther sufficient nor necessary to confer protective immunity in
the murine model of chlamydial genital infection (27, 43).
These data from both animal models and human immunity to
chlamydial infection suggest that an ideal vaccine would be one
that induces both a strong mucosal antibody response and a
strong Th1 CD4-T-cell response. Current knowledge relating
to induction of Th1 and Th2 responses and the reciprocal
down-regulation of each response by an established T-cell re-
sponse of the opposite type (reviewed in reference 46) suggests
that this type of immune response may be difficult to induce.
Furthermore, both the humoral and cell-mediated components
of a vaccine-induced response would need to be targeted to the
female reproductive tract (FRT), something not achieved by
conventional injectable vaccines.
In this study we have used a novel immunization method,
transcutaneous immunization (TCI) (16), that we have previ-
ously shown to efficiently target immune responses to the mu-
rine FRT (18). We have also used a combination of cholera
toxin (CT) and CpG oligodeoxynucleotide (CpG-ODN) DNA
as adjuvants in these studies. CpG-ODN are potent adjuvants
in many species, and when they are administered by parenteral,
oral, or intranasal route, they induce predominantly Th1 im-
mune responses (40, 41). CT is a potent adjuvant for induction
of mucosal IgA responses when administered by either the oral
or intranasal route (11, 12) but elicits mainly IgG responses
when administered transcutaneously (16, 17). TCI of female
mice with C. muridarum (formerly the mouse pneumonitis
strain of C. trachomatis) MOMP admixed with both CT and
CpG-ODN induced MOMP-specific IgG and IgA in vaginal
and uterine lavage fluid together with IFN--secreting T cells
in reproductive tract-draining caudal and lumbar lymph nodes
(CLN). This immunization protocol resulted in enhanced
clearance of C. muridarum following intravaginal challenge of
BALB/c mice.
MATERIALS AND METHODS
Mice. Specific-pathogen-free female BALB/c mice were obtained from the
Central Animal House, The University of Newcastle. Animals were housed
under a standard day-night cycle and provided with sterile food and water ad
libitum. All procedures were approved by the University of Newcastle Animal
Care and Ethics Committee.
Purification of recombinant MOMP. The transformed Escherichia coli
(DH5{pMMM3}) expressing the pMAL-c2 vector encoding recombinant mal-
tose binding protein (MBP)-MOMP fusion protein was a generous gift from
Harlan Caldwell (Rocky Mountain Labs, Hamilton, Mont.) (61). Following over-
night culture on ampicillin-supplemented nutrient agar plates, a single colony
was selected from the plate and grown overnight in 20 ml of ampicillin-contain-
ing medium (Luria-Bertani broth; Bacto, Liverpool, Australia). This 20 ml was
then used to inoculate 1 liter of ampicillin-containing medium, which was then
grown overnight at 37°C on a shaker incubator at 200 rpm. The next day, 3 ml of
0.1 M isopropyl--D-thiogalactopyranoside (IPTG) (Sigma-Aldrich, Castle Hill,
Australia) was added to the culture, which was incubated for a further 2 h.
Bacteria were harvested by centrifugation and the pellet was washed twice with
phosphate-buffered saline (PBS) (Trace Biosciences, Sydney, Australia). The
pellet was resuspended in 40 ml of PBS and then sonicated on ice eight times, for
15 s on and 15 s off, at an amplitude of 7 (Soniprep 150-MSE; Townson and
Mercer Pty. Ltd.). After centrifugation at 8,500 rpm with a Beckman J-12 cen-
trifuge, the pellet was washed twice with PBS and resuspended in 10 ml of 8 M
urea containing 100 l of protease inhibitor cocktail (Sigma-Aldrich) for 2 h at
37°C. The solution was centrifuged to recover the soluble supernatant containing
the MOMP. The MBP-MOMP protein was purified using a PD-10 Sephadex
column (Amersham Biosciences, Baulkham Hills, Australia) followed by a Seph-
adex G-75 column (Sigma-Aldrich) and concentrated using an Amicon Cen-
triprep concentrator (Millipore, North Ryde, Australia) with a 50,000-molecular-
weight-cutoff filter. The protein concentration of each batch was determined
using a Pierce protein estimation kit (Progen Industries, Darra, Australia). Char-
acterization of the MOMP was performed for all batch samples by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis using 15% sodium dodecyl
sulfate gels (Bio-Rad Laboratories Pty Ltd., Reagents Park, Australia) to ensure
the presence of the predicted 80-kDa MBP-MOMP polypeptide consistent with
the combined mass of MBP (42 kDa) and MOMP (39 kDa). MBP-MOMP
samples were frozen at 20°C until required.
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TCI. Female BALB/c mice, 6 to 10 weeks old, were anesthetized intraperito-
neally with xylazine hydrochloride (Rompun; Bayer, Sydney, Australia) and
ketamine (Parnell Laboratory, Castle Hill, Australia). The lower back region (1
cm2) of each mouse was shaved, with care taken not to break the skin. The
shaved area was swabbed with acetone followed by sterile PBS and allowed to
dry. A 50-l volume of PBS containing 200 g of MBP-MOMP admixed with 10
g of CpG-ODN (5	-TCC ATG ACG TTC CTG ACG TT-3	), control ODN
5	-TCC AGG ACT TTC CTC AGG TT-3	 (Geneworks, Rundle Mall, Australia)
(28), and 10 g of CT adjuvant (Sigma-Aldrich) was applied to the shaved area.
The mice were maintained under anesthesia for 30 min to prevent grooming and
oral immunization. After 30 min the application site was swabbed thoroughly
with PBS. Immunizations were administered weekly for three consecutive weeks,
followed by a 6-week booster. Nonimmunized controls were included in all
experiments.
Collection of serum, vaginal lavage fluid, and uterine lavage fluid samples.
Serum and vaginal lavage fluid samples were collected preimmunization, post-
third immunization, and post-6-week booster. Vaginal lavage fluid samples were
collected by flushing the vagina with 40 l of sterile PBS. Blood was collected
from the saphenous vein into nonheparinized capillary tubes and then trans-
ferred to sterile 0.5-ml Eppendorf tubes and allowed to clot. Serum was sepa-
rated by centrifugation and frozen at20°C until required. At sacrifice the entire
FRT was removed and the uterine horns were cut at the level of the uterine
corpus. The ovary and oviducts were removed, and each uterine horn was flushed
with 100 l of PBS containing protease inhibitors. Uterine lavage fluids were
frozen at 20°C until assayed.
MOMP-specific IgG (IgG1/IgG2a) and IgA ELISA. Levels of MOMP-specific
IgA and IgG (IgG1/IgG2a) in serum and vaginal lavage fluid were determined by
enzyme-linked immunosorbent assay (ELISA). Falcon 96-well flexiplates were
coated with MBP-MOMP (2 g/well) diluted in borate-buffered solution at pH
9.6 overnight at 4°C. The following day the plates were washed three times with
0.05% Tween 20 in PBS (PBST) and then blocked with 0.05% fetal calf serum
(FCS) (100 l/well) in PBST for 1 h at 37°C. Plates were washed three times with
PBST, and 50 l of sample was added to appropriate wells at 4°C. Vaginal lavage
fluid was serially diluted twofold from 1/20 to 1/160 in PBST. Serum was diluted
twofold from 1/100 to 1/800 in PBST. Background wells contained 50 l of PBST
alone. Plates were covered and incubated at 37°C for 1 h and then washed three
times with PBST. Biotin-conjugated anti-IgA (Southern Biotechnology Associ-
ates, Birmingham, Ala.), anti-IgG (Amersham Life Science, Castle Hill, Austra-
lia), anti-IgG1 (Southern Biotechnology Associates), and anti-IgG2a (Southern
Biotechnology Associates) antibodies were diluted 1/1,000 in PBST, and 50 l
was added to each well of the respective plates. The plates were incubated for 1 h
at 37°C and then washed five times with PBST. Horseradish peroxidase (HRP)-
conjugated streptavidin (Amersham Life Science) diluted 1/1,000 in PBST was
added at 50 l per well. The plates were incubated for 1 h at 37°C and then
washed seven times with PBS. The plates were then developed using a 50-l/well
concentration of tetramethylbenzidine (0.01 mg/ml; Sigma-Aldrich) substrate
dissolved in dimethyl sulfoxide (Sigma-Aldrich) and diluted 1/100 in phosphate
citrate substrate buffer with sodium perborate (Sigma-Aldrich). The reaction was
stopped by addition of 1 M sulfuric acid (50 l/well) after 10 min, and the optical
density of each plate was read at 450 nm.
In vitro neutralization of C. muridarum infectivity. McCoy cells were grown to
80% confluence in 48-well flat-bottom plates. Aliquots (40 l) of diluted vaginal
lavage fluid were incubated with 103 inclusion-forming units (IFU) of C. muri-
darum (C. trachomatis mouse pneumonitis biovar, ATCC VR-123) elementary
bodies (EBs) for 1 h and then serially diluted 1/10 to 1/320 in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% FCS, gentamicin (5 g/ml),
and streptomycin (100 g/ml) before addition to McCoy cell monolayers. In-
fected plates were centrifuged at 2,000 rpm for 30 min at room temperature to
facilitate EB infection of cells. The plate was incubated for 2 h at 37°C with 5%
CO2. The plates were then washed with PBS to remove the unbound EBs.
Cycloheximide at 1 g/ml (Sigma) in DMEM was added to each well, and the
plate was incubated at 37°C for 24 h. The next day, plates were spun at 2,000 rpm
for 30 min at room temperature and fed fresh medium containing cycloheximide.
After 28 to 42 h the plates were stained to visualize active inclusion bodies (IBs)
within the cells. Using this dose of C. muridarum caused infection of approxi-
mately 70% of cells in medium control wells.
Staining of C. muridarum inclusions in infected McCoy cells. McCoy cell
monolayers were washed with PBS and fixed with 100% methanol for 5 min and
then air dried. Endogenous peroxidase was quenched by incubating the wells
with 6% hydrogen peroxide for 5 min at room temperature. The plates were
washed twice with PBS and then blocked for 30 min at 37°C using diluted goat
serum (3 drops in 10 ml of PBS; Jomar Diagnostics, Stepney, Australia). The
blocking solution was removed and 200 l of the primary rabbit anti-C. tracho-
matis antibody (Pierce/Progen, Richlands, Australia), diluted 1 in 200 in PBS,
was added to each well and incubated at 37°C for 1 h before washing twice with
PBS. The secondary anti-rabbit antibody conjugated to HRP (Progen) was made
up fresh (1 drop of secondary antibody conjugate, 3 drops of blocking serum in
10 ml of PBS), 200 l was added to each well, and then the plate was incubated
in a humidified chamber at 37°C for 1 h. The plate was rinsed twice with PBS,
excess fluid was removed, and then fresh ABC reagent (Pierce Immunopure
ABC peroxidase kit; Progen) (2 drops of solution A and 2 drops of solution B in
10 ml of PBS) was added (200 l per well) and the plates were incubated at 37°C
for 30 min. The plate was washed once with PBS for 10 min, and then Immu-
nopure metal-enhanced 3,3-diaminobenzidine substrate (200 l per well; Pro-
gen), diluted 1:10 in PBS was added. The plate was left to incubate at room
temperature until the color developed. The reaction was stopped with the addi-
tion of 100 l of water to each well, and C. muridarum-infected cells were
visualized by light microscopy.
Detection of MOMP-specific ASC in the FRT. MOMP-specific B-cell numbers
were determined by previously described methods (18). Briefly, vaginal and
uterine tissues were fixed in ethanol and embedded in wax, and 5-m-thick
sections were cut. Sections were dewaxed and rehydrated through graded etha-
nol solutions to PBS. Immunoperoxidase staining was used to detect B cells
secreting MOMP-specific antibody. Endogenous peroxidase was quenched by
incubation of sections in blocking solution (4 ml of 30% H2O2, 75 ml of PBS, 75
ml of methanol). MOMP at 16 mg/ml was diluted 1/300 in 10% FCS–PBS, and
150 l was added to each slide. The sections were covered with a coverslip, and
the slides were incubated for 30 min at 37°C prior to washing twice in PBS. The
rabbit anti-MOMP antiserum (see below) was diluted 1/100 with 10% FCS in
PBS, and 150 l was added to each slide. Control slides were incubated in 10%
FCS in PBS. Slides were topped with coverslips, incubated for 1 h at 37°C, and
then washed twice with PBS. HRP-conjugated sheep anti-rabbit IgG (Silenus,
Melbourne, Australia) was diluted 1/100 in 10% FCS–PBS, and 150 l was added
to all slides for 1 h at 37°C. Slides were then washed twice with PBS, and sections
were developed in 3,3-diaminobenzidine (Vector DAB kit) for 5 min and then
counterstained with hematoxylin. Irrelevant antibody of the same species and
isotype was used as a control for nonspecific antibody binding at each step.
Sections were photographed using a Spot Junior camera (Diagnostic Instru-
ments, Sydney, Australia), and numbers of MOMP-specific antibody-secreting
cells (ASC) per 40
 field were determined using Image Pro Plus 4 software
(Media Cybernetics). For each experimental group vaginal tissues from three
animals were embedded in a single block. For calculation of the numbers of ASC
per field, 10 random fields per experimental group were counted.
Production of rabbit anti-MOMP antiserum. Rabbits (specific pathogen free,
outbred, lop-eared) were immunized subcutaneously with 0.5 mg of MOMP
suspended in complete Freund’s adjuvant (Sigma-Aldrich). Three and five weeks
later animals were immunized with 0.5 mg of MOMP suspended in incomplete
Freund’s adjuvant (Sigma-Aldrich). Each animal was bled 1 week after the final
immunization. Serum was isolated from clotted whole blood by centrifugation
and incubated for 1 h at 4°C with 107 BALB/c spleen cells per ml of serum.
Aliquots of the adsorbed serum were stored at 20°C for later use in histology.
Determination of cytokine mRNA expression by T cells in CLN following in
vitro stimulation with MOMP. CLN were removed from immunized and control
mice. Pooled CLN cells were isolated by passage of LN through a nylon cell
strainer (Becton Dickinson, Sydney, Australia). The cells were washed two times
in Hanks buffered salt solution and suspended in complete DMEM (DMEM
supplemented with 10% FCS, L-glutamine, 5 
 105 M 2-mercaptoethanol,
HEPES buffer, penicillin-streptomycin, and amphotericin B [Fungizone], all
from Trace Biosciences) at a concentration of 2 
 106 cells per ml. Cells were
divided into aliquots in 24-well plates (1 ml per well) and stimulated with MOMP
(final concentration, 5 g/ml) overnight at 37°C in 5% CO2. After overnight
incubation, cells were washed two times in Hanks buffered salt solution prior to
isolation of RNA. Total RNA was isolated from stimulated and control LN cells
by homogenization in 1 ml of solution A (50 ml of solution B [4 M guanidinium
isothiocyanate, 25 mM sodium citrate, pH 7, and 0.5% sarcosyl] [Sigma-Aldrich])
to which was added 360 l of 2-mercaptoethanol (Sigma-Aldrich). To each
sample was added 100 l of 2 M sodium acetate made up in 0.1% diethyl
pyrocarbonate water (Sigma-Aldrich), 1 ml of phenol, and 200 l of chloroform-
isoamyl alcohol (Sigma-Aldrich), mixing well after each addition. Tubes were
vortexed vigorously for 10 s and then centrifuged at 8,000 rpm for 20 min at 4°C.
The aqueous phase was then transferred to a fresh tube and 1 ml of isopropanol
(BDH, Sydney, Australia) was added, the solution was mixed, and the tube was
placed at 20°C for at least 1 h. The mixture was then centrifuged at 8,000 rpm
for 30 min at 4°C, the supernatant was discarded, and the pellet was resuspended
in 300 l of solution A. Three hundred microliters of isopropanol was added, and
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the mixture was placed at 20°C overnight. The next day the RNA mixture was
centrifuged at 8,000 rpm for 20 min at 4°C. The pellet was then washed twice,
first with 100% ethanol to precipitate the RNA and then with 70% ethanol, and
allowed to air dry to remove all traces of ethanol. The pellet was then dissolved
in 100 l of diethyl pyrocarbonate water. Samples were diluted 1/50, and absor-
bance at 260/280 nm was measured to determine the concentration. RNA (200
g) was then reverse transcribed using 6 g of random hexamers (Invitrogen,
Mount Waverley, Australia), 1 l of 10 mM PCR nucleotide mix (Invitrogen), 5
l of 5
 First-strand buffer (Invitrogen), and 5 l of RNase OUT (Invitrogen).
The reaction mixture was made up to 25 l with RNase-free water, heated to
65°C for 5 min, and then transferred to 37°C for 5 min. Then, 1 l of reverse
transcriptase (Superscript II, Invitrogen) was added to each reaction tube, and
the tubes were incubated for a further hour at 37°C. The tube was then heated
for 5 min at 95°C and then cooled to 4°C and frozen at 20°C or left on ice for
immediate use in the PCR. Real-time PCRs were set up in PCR tubes with a final
reaction volume of 25 l. This technique used flanking nucleotide primers and
Sybergreen with ROX reference dye. Primer sequences were designed using
Primer Express 2.0 software (Applied Biosciences). The sequences of all primers
used in these studies are provided in Table 1. The relative increase in reporter
fluorescent dye emission was monitored in real time during PCR amplification
using the sequence detection system and software (ABI PRISM 7000 sequence
detection system and software; PE Applied Biosystems Inc., Foster City, Calif.)
and PCR was performed as described previously. Briefly, the 25-l reaction
volume contained 2 l of cDNA from the reverse transcription reaction, 0.5 l
of primers and antisense primers, 0.25 l of 100
 Sybergreen dye, and 12.5 l of
Platinum qPCR supermix-UDG (Invitrogen). Beta-actin RNA was used as an
internal standard to control for variability in amplification due to differences in
initial RNA concentrations. The level of the cytokine RNA, relative to beta-actin
RNA, was calculated using the following formula: relative RNA expression 
2
(Ct of cytokine  Ct of beta actin)

 1010, where Ct is on the threshold cycle value (70).
Since the level of cytokine RNA was considerably lower than the level of beta-
actin RNA, all RNA values were arbitrarily multiplied by 1010.
Intravaginal challenge with C. muridarum. Seven days prior to intravaginal
challenge all mice received 2.5 mg of medroxyprogesterone acetate (Depo-
Ralovera; Kenral, Rydalmere, New South Wales, Australia) subcutaneously. For
intravaginal challenge mice were anesthetized intraperitoneally with Rompun
and ketamine, and 5 
 104 IFU of C. muridarum in 10 l of sucrose-phosphate-
glutamate (SPG) solution was administered into the vaginal vault with the mouse
in a head down position. When mice had recovered from the anesthesia, the
genital region was swabbed to remove any Chlamydia cells from the external area
to avoid oral inoculation as a result of grooming. The mice were then returned
to their cages and housed under biosafety PC2 conditions.
Monitoring clearance of intravaginal inoculation by real-time PCR. Vaginal
swabs were collected at 3-day intervals from day 0 to 21 of infection. The vagina
was swabbed using a nasopharyngeal Calgiswab (Modular Medical Products,
Alice Springs, Australia) moistened with ice-cold sterile SPG. The swab was then
placed into an Eppendorf tube containing 500 l of SPG and a single glass bead,
the end of the swab was removed, and the tube was left on ice for immediate
DNA extraction or frozen at 20°C. Total DNA was extracted using an Am-
plicore CT/NG specimen preparation kit (Roche, Castle Hill, Australia) accord-
ing to the manufacturer’s instructions. The swab sample was vortexed vigorously
for 30 s, the swab was removed, and 100 l of sample was removed to a new
Eppendorf tube. This aliquot was combined with 50 l of CT/NG lysis buffer,
vortexed for 30 s, and incubated at room temperature for 10 min. One hundred
microliters of CT/NG specimen diluent was then added, vortexed briefly, incu-
bated at room temperature for 10 min, and then stored at 4°C overnight. Real-
time PCR was used to quantify the amount of Chlamydia present in the vaginal
swabs. The real-time PCR used flanking nucleotide primers specific for C. muri-
darum MOMP, as can be seen in Table 1, and Sybergreen dye with ROX
reference dye. The relative increase in reporter fluorescent dye emission was
monitored in real time during PCR amplification using the sequence detection
system (ABI PRISM 7000 sequence detection system and software; PE Applied
Biosystems, Inc.). PCR was performed in a 25-l reaction volume that contained
2 l of DNA extracted from vaginal swabs, 20 mM sense and antisense primers,
1
 Sybergreen dye (0.25 l of 100
 stock), and Platinum qPCR Supermix-UDG
with ROX added (12.5 l). For each assay a standard curve using C. muridarum
standards, determined by infection of McCoy cells as outlined above, was run
simultaneously with the samples to allow for quantification using ABI PRISM
7000 software (PE Applied Biosystems).
Statistics. The significance of differences in the numbers of Chlamydia-positive
McCoy cells between cultures preincubated with immune and nonimmune vag-
inal lavage and uterine lavage fluids was determined by unpaired two-tailed t test.
The significance of differences in numbers of MOMP-specific ASC in vaginal
tissues was determined by one-way analysis of variance with a Bonferroni post-
test. The significance of differences in the rates of clearance of C. muridarum
between immunized and control mice were determined using Kaplan-Meier
survival curves and the log rank test.
FIG. 1. CpG as adjuvants for TCI. Female BALB/c mice were
immunized with MOMP mixed with either CT (10 g) or CpG-ODN
(10 g) or control ODN by direct application to skin as described in
Materials and Methods MOMP-specific IgG in serum (1:200 dilution)
was determined by ELISA. Results are representative of four separate
experiments. Error bars, standard deviations.
TABLE 1. Sequences of primers used in this study
Gene product Primer Sequence
Beta-actin Forward 5	 AGA GGG AAA TCG TGC GTG AC 3	
Reverse 5	 CAA TAG TGA TGA CCT GGC CGT 3	
IFN- Forward 5	 TCA AGT GGC ATA GAT GTG GAA GAA 3	
Reverse 5	 TGG CTC TGC AGG ATT TTC ATG 3	
IL-4 Forward 5	 GGC ATT TTG AAC GAG GTC ACA 3	
Reverse 5	 AGG ACG TTT GGC ACA TCC AT 3	
C. muridarum MOMP (bp 206–281) Forward 5	 GCC GTT TTG GGT TCT GCT T 3	
Reverse 5	 CGT CAA TCA TAA GGC TTG GTT CA 3	
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RESULTS
CpG-ODN nucleotides as adjuvants for TCI. TCI requires
that bacterial ADP-ribosylating exotoxins be mixed with anti-
gen in order to elicit immune responses (17). The data in Fig.
1 show that CpG-ODN can also enhance responses to antigens
applied directly to the skin. CpG-ODN, at a dose of 10 g,
mixed with 200 g of MOMP, elicited levels of MOMP-specific
serum IgG comparable to those elicited by MOMP adminis-
tered with CT as an adjuvant. In preliminary studies (data not
shown) increasing the CpG-ODN dose to 50 or 100 g did not
result in increased MOMP-specific serum IgG responses. In
some experiments, control oligonucleotides (Fig. 1, negative
control) that did not contain CG dinucleotides also had some
adjuvant effect. Thus, skin-based immunization is also possible
using adjuvants other than ADP-ribosylating exotoxins. Of
greater importance for protection against Chlamydia infection,
TCI using CpG-ODN adjuvant resulted in significant numbers
of MOMP-specific ASC in vaginal tissues. Numbers of vaginal
MOMP-specific ASC in animals immunized with CpG-ODN
adjuvant (Fig. 2c) were twofold greater than ASC numbers in
mice immunized with CT as adjuvant (Fig. 2b). MOMP-spe-
cific ASC numbers in tissues from animals immunized with
MOMP combined with both CT and CpG (Fig. 2d) were not
increased compared to those in tissues from animals immu-
nized with MOMP plus CpG alone. Low numbers of MOMP-
specific ASC were detected in vaginal tissues of animals im-
munized with MOMP alone (Fig. 2a), most likely due to the
LPS present in the MOMP preparation.
TCI using combined CT plus CpG-ODN adjuvant induces
both Th1 and Th2 responses. TCI using CT results in a serum
IgG response that is predominantly IgG1, indicative of a Th2
response (Fig. 3), whereas CpG-ODN induce predominantly
Th1 responses (40). However, when mice were immunized
transcutaneously with both CT and CpG-ODN, the serum IgG
response contained both IgG1 and IgG2a (Fig. 3), indicative of
a mixed Th1-Th2 response.
CpG-ODN increase vaginal lavage fluid IgA and IgG levels
following TCI. TCI, using CT as an adjuvant, induces antigen-
specific IgG and low levels of IgA in vaginal lavage fluid (18)
(Fig. 4). When mice were immunized with MOMP combined
with either CT or CpG or with both CT and CpG-ODN,
MOMP-specific IgG was detected in vaginal lavage fluid (Fig.
4a). Levels of IgG did not differ significantly depending on the
adjuvant used. Interestingly, TCI with CpG plus MOMP re-
sulted in higher levels of IgA in vaginal lavage fluid than that
found in animals immunized with CT or CT plus CpG adjuvant
(Fig. 4b). Furthermore, preincubation of C. muridarum with
vaginal lavage fluid or uterine lavage fluid from mice immu-
nized with MOMP mixed with both CT and CpG-ODN inhib-
ited in vitro infection of McCoy cells by 45 to 60% at a dilution
FIG. 2. MOMP-specific ASC in vaginal tissues. Vaginal tissues from mice immunized transcutaneously with MOMP alone (a), MOMP plus CT
(b), MOMP plus CpG-ODN (c), and MOMP plus CT and CpG-ODN (d) were stained for MOMP-specific ASC as described in Materials and
Methods. Magnification, 
10 (magnification for insets, 
40). The numbers of ASC per field in each of the large panels (mean  standard error
of the mean) were as follows: 2.2 0.53, 4.4 0.63, 7.5 0.79, and 7.9 1.4, respectively. Differences between numbers of ASC in panels a versus
b and panels c versus d were not significant; differences between numbers of ASC in panels a versus c and a versus d were significant (P  0.01]).
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of 1:160 (Table 2), demonstrating that antibody in both upper
and lower reproductive tract secretions could potentially pre-
vent attachment of Chlamydia and reduce sexual transmission.
Combination CT plus CpG-ODN adjuvant induces IFN-
mRNA expression by CLN cells. Local Th1 responses have
been implicated in clearance of Chlamydia from the genital
tract. We therefore isolated mononuclear cells from the repro-
ductive-tract-draining CLN of immunized mice, stimulated
these in vitro with MOMP, and used real-time PCR to deter-
mine the relative levels of IFN- and interleukin 4 (IL-4)
mRNA (Fig. 5). CLN cells from mice immunized with MOMP
alone showed an 11-fold increase in IL-4 mRNA compared to
cells from nonimmunized mice following in vitro stimulation.
Immunization of mice with MOMP plus CT resulted in a six-
to sevenfold increase in IL-4 mRNA levels in CLN cells, with
a three- to fourfold increase in IFN- mRNA. In vitro stimu-
lation of CLN cells from mice immunized with MOMP plus
CpG resulted in a 75- to 80-fold increase in IFN- mRNA and
a 5- to 6-fold increase in IL-4 mRNA. In vitro stimulation of
CLN cells from mice immunized with MOMP plus combined
CT and CpG-ODN adjuvant resulted in an even greater, 90- to
105-fold increase in IFN- mRNA expression, while IL-4
mRNA levels were 15-fold higher than levels seen in cells from
nonimmunized control mice, levels still higher than those
found in animals immunized with MOMP plus CT.
TCI enhances clearance of C. muridarum following vaginal
challenge. Vaginal swabs were collected at 3-day intervals from
mice immunized with MOMP admixed with both CT plus
FIG. 3. Combination CT plus CpG-ODN adjuvant enhances IgG2a
production. Female BALB/c mice were immunized with MOMP mixed
with either CT alone or both CT and CpG-ODN by direct application
to skin as described in Materials and Methods. MOMP-specific IgG2a
(upper panel) and IgG1 (lower panel) in serum (1:200 dilution) were
determined by ELISA. Results are representative of three separate
experiments. The y axis shows optical density at 450 nm. Error bars,
standard deviations.
FIG. 4. MOMP-specific IgG and IgA in vaginal lavage fluid follow-
ing TCI. Female BALB/c mice were immunized with MOMP mixed
with either CT alone, CpG alone, or both CT and CpG-ODN by direct
application to skin as described in Materials and Methods. MOMP-
specific IgG (upper panel) and IgA (lower panel) in vaginal lavage
fluid (1:40 dilution) were determined by ELISA. Results are represen-
tative of three separate experiments. Error bars, standard deviations.
TABLE 2. McCoy cells containing inclusionsa
Lavage fluid
sample
Expt
no.
% McCoy cells containing
inclusions (mean  SD) P
Nonimmune Immune
Vaginal 1 57.6  3.7 31.7  3.6 0.0002
2 67.6  6.7 24.4  11.1 0.01
Uterine 1 78.9  1.2 39.3  1.3 0.0001
2 75.3  0.5 33.9  1.6 0.0001
a C. muridarum was incubated for 1 h with vaginal and uterine lavage fluids
from immunized or nonimmunized mice prior to plating onto McCoy cell mono-
layers. After 24 to 40 h of incubation, McCoy cell monolayers were fixed and
stained to reveal chlamydial IBs. Results represent McCoy cells containing chla-
mydial inclusions. The dose of Chlamydia used resulted in infection of approx-
imately 70% of the McCoy cells in the medium-only control cultures. All samples
were tested in triplicate, and the results are representative of four separate
experiments.
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CpG-ODN and nonimmunized control mice. Total DNA was
extracted from swabs, and chlamydial DNA was determined by
real-time PCR (Fig. 6). Standard curves were generated in
each assay using C. muridarum standards that had been quan-
titated for IFU by in vitro infection of McCoy cells. At 6 days
postinfection, levels of Chlamydia recovered from immunized
animals were less than half that recovered from nonimmunized
controls. By day 12 postinfection chlamydial DNA was below
the limits of detection in swabs from four of five immunized
mice but readily detected in five of five nonimmunized con-
trols. All immunized mice had cleared the infection by day 15,
and vaginal swabs from immunized mice remained negative
out to day 21 when the experiment was terminated. At day 21
two of five control animals still had detectable chlamydial
DNA in their vaginal lavage fluid. The rate of clearance of
Chlamydia in immunized mice was significantly higher (P 
0.02) than that seen in nonimmunized controls.
DISCUSSION
The present studies show that CpG-ODN can function ei-
ther alone or in combination with CT as effective adjuvants for
TCI, inducing serum IgG responses and ASC in vaginal tissues.
TCI with a combination of CT plus CpG-ODN induces both
IgG1 and IgG2a in serum, indicative of a mixed Th1-Th2
response. The combination adjuvant also elicits antigen-spe-
cific IgG and IgA in vaginal lavage fluid. Vaginal and uterine
lavage fluid from animals immunized transcutaneously with
MOMP mixed with both CT and CpG-ODN inhibited in vitro
chlamydial infection of McCoy cells. Stimulation of CLN cells
from immunized mice resulted in high levels of IFN- mRNA
production, indicative of a strong Th1 response, together with
moderate levels of IL-4 mRNA, characteristic of Th2 re-
sponses. Immunized mice showed significantly enhanced clear-
ance of Chlamydia following vaginal challenge.
Bacterial DNA containing nonmethylated CG sequences is a
strong activator of innate immunity, activating phagocytic cells
by binding to Toll-like receptor 9 (22). This property has re-
FIG. 5. IFN- and IL-4 mRNA expression by CLN cells. CLN cells
from mice immunized transcutaneously with MOMP alone, MOMP
plus CT, MOMP plus CpG, and MOMP plus CT and CPG-ODN were
stimulated overnight with MOMP. mRNA was isolated from cultures,
and levels of IFN- (dark bars) and IL-4 (light bars) mRNA, relative
to nonimmunized control cultures, were determined by real-time PCR
(70). Results are representative of three separate experiments.
FIG. 6. TCI enhances clearance of vaginal C. muridarum. Vaginal swabs were collected at 3-day intervals from immunized and control mice
following intravaginal challenge with C. muridarum. DNA was extracted from vaginal swabs, and relative levels of Chlamydia DNA were
determined by real-time PCR. The significance of differences in the rates of clearance of C. muridarum between immunized (dark bars) and control
(light bars) mice was determined using Kaplan-Meier survival curves and the log rank test. Results are representative of three separate
experiments. Error bars, standard deviations.
VOL. 72, 2004 TCI TO TARGET GENITAL CHLAMYDIA INFECTION 1025
 o
n
 February 27, 2013 by QUEENSLAND UNIV OF TECH
http://iai.asm
.org/
D
ow
nloaded from
 
sulted in the use of synthetic ODN containing CG motifs as
adjuvants (32, 41). CpG-ODN has been shown to be an effec-
tive adjuvant when administered by subcutaneous, intramus-
cular, oral, rectal, and nasal routes (39) and induces immune
responses that are predominantly Th1 (8, 65). For our studies,
we chose CpG-ODN that had been shown to enhance the
expression of the costimulatory molecules MHC-II and CD86
on cutaneous Langerhans cells and to increase IL-12 produc-
tion and accessory cell function by Langerhans cells (28), be-
cause these cells are involved in initiation of immune responses
following application of antigen to the skin (55). As shown in
Fig. 1, CpG-ODN can also function as effective adjuvants for
antigens applied directly to the skin, for induction of serum
IgG responses. TCI using CpG-ODN also induced high num-
bers of ASC in vaginal tissues (Fig. 2c), higher numbers than
those seen in animals immunized with MOMP plus CT (Fig.
2b). Interestingly, in some experiments we found that control
non-CG-containing ODN also enhanced serum and mucosal
responses to the coadministered MOMP. This effect has also
been observed in other studies (64), in which methylated ODN
longer than 24 nucleotides and with a phosphorothioate back-
bone retained immunostimulatory properties. ODN rich in
thymidine residues were also shown to be immunostimulatory
in the absence of CG dinucleotide sequences. While immuno-
stimulatory CpG-ODN have been identified for humans and
many animal species (2, 20, 30, 33, 44, 53, 62) and can there-
fore be used as adjuvants, the design of optimum CpG-ODN
adjuvants for any particular application must consider features
such as the type of backbone, length, and thymidine content.
Protection against genital tract Chlamydia infection requires
that immune responses be targeted to the FRT. We have
previously shown that TCI is particularly effective at inducing
immunity in the lower (vagina) (18) and upper (uterine horns
[Skelding et al., unpublished data]) FRT. This has also been
demonstrated in the present study. Furthermore, the type of
immune response induced must be appropriate for the patho-
gen, in this case Chlamydia. Both Th1-cell-mediated immunity
and antibody responses have been shown to protect against
genital tract Chlamydia infection in mouse, guinea pig, and
primate models. The relative role of cell-mediated versus hu-
moral immunity will likely depend mainly on the numbers of
infectious Chlamydia used in a particular study. For example,
one study that claims to show that mucosal IgA is not protec-
tive (29) used a challenge dose of 107 C. trachomatis EBs.
However there are numerous studies using challenge doses in
the range of 102 to 105 IFU of Chlamydia that show a protec-
tive effect for both IgG and IgA antibodies (9, 43, 50, 60). With
regard to the efficacy of any potential human vaccine for Chla-
mydia, it is not known how many IFU of Chlamydia are present
in the ejaculate of an infected male. This will obviously have a
major bearing on the effectiveness of vaccine-induced immu-
nity. Using the guinea pig model of Chlamydia genital tract
infection, Rank et al. (52) showed that the number of chla-
mydial agents of guinea pig inclusion conjunctivitis transmitted
by infected males is in the range of 101 to 103, a dose at which
vaginal antibodies are certainly protective. Thus, an ideal vac-
cine may be one that induces both Th1 CMI plus a strong
mucosal antibody response. Th1-T-cell production of IFN-
can protect against the intracellular reticulate body (RB) form
of Chlamydia by one or more of three mechanisms. These
include up-regulation of inducible nitric oxide synthase expres-
sion resulting in nitric oxide production by macrophages (7,
26); induction of indoleamine 2,3-dioxygenase, which degrades
intracellular stores of tryptophan, an amino acid that Chla-
mydia has only a limited ability to produce (26, 47); and down-
regulation of transferrin receptor expression on the surfaces of
infected cells, which would decrease intracellular iron stores
(26). Th1 cells secreting IFN- have been shown to be protec-
tive in animal models (10, 48), while Chlamydia-specific Th2
clones do not provide protection against genital infection (21).
Antibody may also mediate protection by a number of mech-
anisms, including blocking the initial attachment of Chlamydia
to epithelial cells and prevention of subsequent ascending in-
fection, enhancing killing of opsonized Chlamydia by phago-
cytic cells, thereby limiting dissemination to distant sites and
enhancing the resolution of intracellular infection by antibody-
dependent cellular cytotoxicity (42). IgA in vaginal secretions
may also be able to target the intracellular chlamydial RBs due
to the fact that the IgA transporter molecule, the polymeric
immunoglobulin receptor (PIgR), has been shown to be
present on epithelial cells in the rodent (67) and human (34)
FRT. PIgR-mediated transport of IgA across epithelial cells
provides an opportunity to target intracellular pathogens (37,
38). Intraepithelial cell neutralization of viruses by IgA has
been demonstrated both in vitro and in vivo (37). IgA antibod-
ies against viral envelope proteins can neutralize Sendai and
influenza virus infections in polarized epithelial cell monolay-
ers that express the PIgR. IgA antibodies against murine ro-
tavirus and murine hepatitis virus neutralize viruses in vivo
inside intestinal epithelial cells and hepatocytes, respectively
(5, 25). Thus, an immunization protocol that elicits IgA anti-
bodies against both surface antigens on the EB and antigens
associated with the inclusion membrane of Chlamydia, such as
the Inc proteins (54), may provide increased protection against
infection. Although chlamydiae are able to inhibit phagolyso-
some formation as a means of enhancing intracellular growth,
it is not currently known if replication of Chlamydia within the
IB is susceptible to neutralization by IgA during transepithelial
transport. We are currently using in vitro models of chlamydial
infection of PIgR cell lines to determine if IgA can target the
intracellular RB stage.
The present studies have demonstrated that TCI with com-
bination CT plus CpG-ODN adjuvant fulfills all of the criteria
for an effective vaccine against genital tract Chlamydia infec-
tion; specifically, the response is targeted to the site of infec-
tion, the FRT; neutralizing antibody (both IgG and IgA) is
induced in vaginal and uterine secretions; and a strong Th1
IFN- response is elicited in the reproductive-tract-draining
LN. This immunization strategy could easily be tested in hu-
mans due to the availability of CpG-ODN that are immunos-
timulatory for human lymphocytes and nontoxic mutant CT
that retains adjuvant properties (35, 71–73). Furthermore, the
application of CT, either wild-type or mutant forms, directly to
skin further reduces the chance of toxic side effects that occur
following oral ingestion of CT and also avoids potential toxicity
of CT for the central nervous system (15, 63) that may occur
following intranasal administration. Both CT and its  subunit
have been shown to accumulate in the olfactory nerves or
epithelium and olfactory bulbs of mice when given by the nasal
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route, something that could limit the utility of intranasal im-
munization in humans.
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